{"title":"Current role of high dose vitamin C in sepsis management: A concise review.","authors":"Deven Juneja, Prashant Nasa, Ravi Jain","doi":"10.5492/wjccm.v11.i6.349","DOIUrl":null,"url":null,"abstract":"<p><p>Sepsis and septic shock are common diagnoses for patients requiring intensive care unit admission and associated with high morbidity and mortality. In addition to aggressive fluid resuscitation and antibiotic therapy, several other drugs have been tried as adjuvant therapies to reduce the inflammatory response and improve outcomes. Vitamin C has been shown to have several biological actions, including anti-inflammatory and immunomodulatory effects, which may prove beneficial in sepsis management. Initial trials showed improved patient outcomes when high dose vitamin C was used in combination with thiamine and hydrocortisone. These results, along with relative safety of high-dose (supra-physiological) vitamin C, encouraged physicians across the globe to add vitamin C as an adjuvant therapy in the management of sepsis. However, subsequent large-scale randomised control trials could not replicate these results, leaving the world divided regarding the role of vitamin C in sepsis management. Here, we discuss the rationale, safety profile, and the current clinical evidence for the use of high-dose vitamin C in the management of sepsis and septic shock.</p>","PeriodicalId":66959,"journal":{"name":"世界危重病急救学杂志(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/52/WJCCM-11-349.PMC9693906.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界危重病急救学杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5492/wjccm.v11.i6.349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sepsis and septic shock are common diagnoses for patients requiring intensive care unit admission and associated with high morbidity and mortality. In addition to aggressive fluid resuscitation and antibiotic therapy, several other drugs have been tried as adjuvant therapies to reduce the inflammatory response and improve outcomes. Vitamin C has been shown to have several biological actions, including anti-inflammatory and immunomodulatory effects, which may prove beneficial in sepsis management. Initial trials showed improved patient outcomes when high dose vitamin C was used in combination with thiamine and hydrocortisone. These results, along with relative safety of high-dose (supra-physiological) vitamin C, encouraged physicians across the globe to add vitamin C as an adjuvant therapy in the management of sepsis. However, subsequent large-scale randomised control trials could not replicate these results, leaving the world divided regarding the role of vitamin C in sepsis management. Here, we discuss the rationale, safety profile, and the current clinical evidence for the use of high-dose vitamin C in the management of sepsis and septic shock.
败血症和脓毒性休克是需要入住重症监护室的病人的常见诊断,与高发病率和高死亡率有关。除了积极的液体复苏和抗生素治疗外,还尝试了其他几种药物作为辅助疗法,以减轻炎症反应并改善预后。维生素 C 已被证明具有多种生物作用,包括抗炎和免疫调节作用,可能对败血症治疗有益。初步试验显示,大剂量维生素 C 与硫胺素和氢化可的松联合使用可改善患者的预后。这些结果以及大剂量(超生理剂量)维生素 C 的相对安全性鼓励全球医生在败血症治疗中加入维生素 C 作为辅助疗法。然而,随后进行的大规模随机对照试验却无法复制这些结果,导致全世界对维生素 C 在败血症治疗中的作用存在分歧。在此,我们将讨论在脓毒症和脓毒性休克治疗中使用大剂量维生素 C 的原理、安全性概况和目前的临床证据。